Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XOMA vs AGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGEN Captures Overall Composite Edge (52.7 HOLD vs 55.8 HOLD), While XOMA Leads 3–2 on Growth & Valuation Pillars

AGEN Overall Winner 6-Pillar Tally: XOMA 3 – 2 AGEN (1 Tie) Matrix Metrics: XOMA 7 – 3 AGEN

As of Nov 16, 2026, Agenus Inc. (AGEN) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (52.7/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while XOMA wins 3–2 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus AGEN at $6.34 (3.7x Forward P/E, 38.9% operating margin).

  • Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. AGEN 52.7/100 HOLD), AGEN captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -3.9% operating margin) and revenue trajectory (+4.1% vs. -22.6% YoY).
  • Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs AGEN
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
AGEN NASDAQ Head-to-Head Winner
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.34
-5.79% 1D
Market Cap $310.8M
TTM Revenue $34M
Forward P/E 3.7x
Beta / 30D Vol 1.60β · 76% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 42
RSI-14: 42.0 · SMA20: $6.73 · SMA50: $7.33

6-Pillar Scorecard Institutional Category Breakdown (XOMA 3 – 2 AGEN)

Columns: Metric · XOMA · AGEN
1. Valuation Multiples AGEN
Forward P/E 21.5x 3.7x
Trailing P/E 28.2x 29.9x
PEG Ratio N/M 1.44x
EV / Revenue 16.1x 8.9x
2. Growth & Scale XOMA
Revenue Growth (YoY) -22.6% +4.1%
Earnings Growth (YoY) +207.9% -99.0%
TTM Revenue (USD) $49M $34M
Market Cap $781.8M $310.8M
3. Profitability & Quality XOMA
Gross Margin 99.0% N/A
Operating Margin -3.9% 38.9%
Net Profit Margin 69.6% 30.8%
Return on Equity (ROE) 34.2% -1278.8%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA -$35M
Cash Flow Margin 17.1% EBITDA Mgn -103.7%
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $9.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGEN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 101.5% (100th %ile) 95.2% (11th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (7) vs AGEN (3)
Institutional Metric XOMA AGEN Criterion Row Edge
Market Capitalization
Scale
$781.8M $310.8M Larger Scale XOMA
Trailing P/E Ratio
Valuation
28.2x 29.9x Lower Multiple XOMA
Forward P/E Ratio
Valuation
21.5x 3.7x Lower Multiple AGEN
Revenue Growth (YoY)
Growth
-22.6% +4.1% Higher Growth AGEN
Operating Margin (TTM)
Profitability
-3.9% 38.9% Higher Margin AGEN
Net Profit Margin
Profitability
69.6% 30.8% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% -1278.8% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 48% ($3–$10) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 1.60β · 76% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 52.7 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$49M $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev 1.44x PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) -$35M ($9.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AGEN +103.16 pp
XOMA: -3.81% · AGEN: +99.35%
3M Horizon AGEN +45.21 pp
XOMA: +9.34% · AGEN: +54.55%
6M Horizon AGEN +28.94 pp
XOMA: +34.26% · AGEN: +63.2%
1Y Horizon AGEN +16.74 pp
XOMA: +24.6% · AGEN: +41.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs AGEN. Trailing 12-month operating profitability (XOMA -3.9% vs AGEN 38.9%) and valuation multiples (XOMA 21.5x vs AGEN 3.7x Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
AGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$34M
Gross MarginN/A
Op. Margin38.9%
ROE / Fwd P/E-1278.8% · 3.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AGEN BREAKDOWN
33d in phase · OBV NEUTRAL
Current IV 95.2%
IV Percentile 11th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $310.8M market capitalization and 38.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs AGEN Key Questions & Quantitative Answers

As of Nov 16, 2026, Agenus Inc. (AGEN) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (52.7/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while XOMA wins 3–2 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus AGEN at $6.34 (3.7x Forward P/E, 38.9% operating margin). Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. AGEN 52.7/100 HOLD), AGEN captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -3.9% operating margin) and revenue trajectory (+4.1% vs. -22.6% YoY). Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XOMA leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with AGEN at +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $34M for AGEN. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGEN.

AGEN screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas AGEN trades at 3.7x Forward P/E, 29.9x Trailing P/E, 1.44x PEG, and 8.9x EV/Revenue (-103.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus AGEN (-1278.8% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, AGEN carries 95.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.60β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.